Derivation and validation of SIDIAP-FHP score: A new risk model predicting cardiovascular disease in familial hypercholesterolemia phenotype

Assessment of individual cardiovascular risk, distinguishing primary and secondary prevention, would improve the clinical management of the population with familial hypercholesterolemia. We aimed to develop and validate two risk functions to predict incident and recurrent atherosclerotic cardiovascu...

Full description

Saved in:
Bibliographic Details
Published in:Atherosclerosis 2020-01, Vol.292, p.42-51
Main Authors: Ramos, Rafel, Masana, Luís, Comas-Cufí, Marc, García-Gil, Maria, Martí-Lluch, Ruth, Ponjoan, Anna, Plana, Núria, Alves-Cabratosa, Lia, Marrugat, Jaume, Elosua, Roberto, Dégano, Irene R., Gomez-Marcos, Mauel A., Zamora, Alberto
Format: Article
Language:English
Subjects:
Aged
Atherosclerosis
Atherosclerosis - diagnosis
Atherosclerosis - etiology
Cardiovascular diseases
Cohort Studies
Familial hypercholesterolemia
Female
Humans
Hyperlipoproteinemia Type II - complications
Hyperlipoproteinemia Type II - genetics
Male
Middle Aged
Models, Statistical
Phenotype
Prevention
Retrospective Studies
Risk assessment
Risk Assessment - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Assessment of individual cardiovascular risk, distinguishing primary and secondary prevention, would improve the clinical management of the population with familial hypercholesterolemia. We aimed to develop and validate two risk functions to predict incident and recurrent atherosclerotic cardiovascular disease (ASCVD) in a primary care-based population with familial hypercholesterolemia phenotype (FHP), and to compare their predictive capacity with that of the SpAnish Familial hypErcHolEsterolemiA cohoRT (SAFEHEART) risk equation (SAFEHEART-RE). Data from the Catalan primary care system database (SIDIAP) of patients ≥18 years old with FHP in 2006–2013 were used to develop and validate two risk functions to predict incident and recurrent ASCVD. A validation dataset was also used to compare the model predictive capacity to that of SAFEHEART-RE. The new model (SIDIAP-FHP) included age, diabetes, smoking, sex (male), hypertension, and baseline low-density lipoprotein cholesterol in the primary prevention cohort and age, diabetes, smoking, and disease characteristics (progressive, recent, polyvascular, or included myocardial infarction) in the secondary prevention cohort. The models demonstrated a fair fit: C-Statistic: 0.71 (95%CI:0.68–0.75) in primary prevention and 0.65 (95%CI:0.60–0.70) in secondary prevention (higher than that of SAFEHEART-RE: 0.64 [95%CI:0.60–0.68] and 0.55 [95%CI:0.51–0.59], respectively; both p 
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2019.10.016